- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
March 16, 2023Second Circuit Affirms Record $5.6 Billion Recovery in Antitrust Case
March 10, 2023Robins Kaplan Announces $28 Million Settlement in Case Against For-Profit College’s Directors & Officers
March 9, 2023Robins Kaplan LLP Launches New Professional Development Program
March 19-22, 2023PLRB 2023 Claims Conference
March 29-30, 2023ACI Managed Care Disputes and Litigation
April 3, 2023Conference of Tribal Lending Commissioners
March 13, 2023The Antitrust Case that Could Reshape Professional Golf
February 22, 2023A World Without Noncompetes: Protecting Confidential Information and Trade Secrets
February 7, 2023When Monkey Business Slips Into Trademark Infringement
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Blue Cross Blue Shield of Massachusetts Ramps Up Request for Treble Damages in Mylan Antitrust Case
Competition Law 360, reported this week that the firm's client Blue Cross Blue Shield of Massachusetts filed new documents providing additional information that further supports BCBS Massachusetts' 2005 post-trial motion for individual treble damages against Mylan Laboratories and two other co-defendants.
In 2005, a federal jury found that Mylan, Gyma Laboratories and Cambrex Corporation violated state antitrust laws by entering into exclusive agreements with active pharmaceutical ingredient suppliers that constrained supply and allowed Mylan to artificially inflate prices for two of Mylan's anti-anxiety drugs lorazepam and clorazepate. Damages in excess of $12 million were awarded to BCBS Massachusetts and three other health plans. The post trial motion for treble damages was based on the jury's finding that the antitrust violations were willful.
In the newly submitted filing, BCBS of Massachusetts renews its request for treble damages and contends that a separate malpractice suit Mylan brought against its former antitrust counsel provides crucial information that further supports a treble damage award against each of the three defendants individually.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.